Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer

By sjmartinez • January 14, 2023

Ganatra S, Dani SS, Yang EH, Zaha VG, Nohria A. Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer. JACC CardioOncol. 2022 Dec 20;4(5):616-623. doi: 10.1016/j.jaccao.2022.07.014. PMID: 36636447; PMCID: PMC9830211.

Tags: arrhythmia, B-cell maturation antigen, BCMA, bispecific T-cell engager, BiTE, BiTE therapy, CAR, CAR T-cell therapy, Cardiology/Epi, cardiomyopathy, cardiotoxicity, chimeric antigen receptor, CRS, cytokine release syndrome, heart failure, Hematology/Oncology, HF, ICSR, IL, individual case safety report, interleukin, left ventricular ejection fraction, LVEF, MACE, major adverse cardiovascular event(s), Publications, TIL, tumor-infiltrating lymphocyte, tumor-infiltrating lymphocytes

Prognostic implications of heart failure stages among Chinese community populations: insight from a nationwide population-based study

Zheng C, Cai A, Wang X, Qiu J, Song Q, Gu R, Cao X, Tian Y, Hu Z, Fonarow GC, Lip GYH, Wang Z, Feng[...]

A (cholesterol) crystal clear path to inflammasome activation in atherosclerosis

Li X, Sallam T. A (cholesterol) crystal clear path to inflammasome activation in atherosclerosis. J Lipid Res. 2024 May 3:100554. doi: 10.1016/j.jlr.2024.100554. Epub ahead of[...]

Generalizability of PGS313 for breast cancer risk in a Los Angeles biobank

Shang H, Ding Y, Venkateswaran V, Boulier K, Kathuria-Prakash N, Malidarreh PB, Luber JM, Pasaniuc B. Generalizability of PGS313 for breast cancer risk in a Los[...]